A pre-marketing ALT signal predicts post-marketing liver safety
- 31 August 2012
- journal article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 63 (3), 433-439
- https://doi.org/10.1016/j.yrtph.2012.05.016
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Review article: drug‐induced liver injury in clinical practiceAlimentary Pharmacology & Therapeutics, 2010
- The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reportsAlimentary Pharmacology & Therapeutics, 2010
- Oral medications with significant hepatic metabolism at higher risk for hepatic adverse eventsHepatology, 2009
- Evidence-Based Liver Chemistry Monitoring in Drug DevelopmentPharmaceutical Medicine, 2009
- Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesGastroenterology, 2008
- Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signalsHepatology, 2008
- Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodGastroenterology, 2005
- Outcome and prognostic markers in severe drug-induced liver diseaseHepatology, 2005
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005
- Acute and clinically relevant drug‐induced liver injury: a population based case‐control studyBritish Journal of Clinical Pharmacology, 2004